[{"address1": "2000 Sierra Point Parkway", "address2": "Suite 400", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "415 798 8589", "website": "https://www.tempesttx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen R. Brady J.D., LLM", "age": 53, "title": "CEO, President & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 923235, "exercisedValue": 0, "unexercisedValue": 262204}, {"maxAge": 1, "name": "Mr. Nicholas  Maestas", "age": 42, "title": "VP of Strategy & Finance and Secretary", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 465429, "exercisedValue": 0, "unexercisedValue": 67328}, {"maxAge": 1, "name": "Dr. Samuel  Whiting M.D., Ph.D.", "age": 57, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 667651, "exercisedValue": 0, "unexercisedValue": 93438}, {"maxAge": 1, "name": "Mr. Justin  Trojanowski", "age": 35, "title": "Corporate Controller, Treasurer & Principal Accounting Officer", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lindsay  Young", "title": "Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sharon  Sakai Ph.D., RAC", "title": "Head of Regulatory & Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.1, "open": 2.1, "dayLow": 1.91, "dayHigh": 2.12, "regularMarketPreviousClose": 2.1, "regularMarketOpen": 2.1, "regularMarketDayLow": 1.91, "regularMarketDayHigh": 2.12, "beta": -2.795, "forwardPE": -1.2662338, "volume": 564363, "regularMarketVolume": 564363, "averageVolume": 988993, "averageVolume10days": 530130, "averageDailyVolume10Day": 530130, "bid": 1.89, "ask": 1.95, "bidSize": 100, "askSize": 400, "marketCap": 43323736, "fiftyTwoWeekLow": 0.17, "fiftyTwoWeekHigh": 9.77, "fiftyDayAverage": 2.7919, "twoHundredDayAverage": 3.51902, "currency": "USD", "enterpriseValue": 31368666, "floatShares": 17727822, "sharesOutstanding": 22217300, "sharesShort": 1880271, "sharesShortPriorMonth": 1635355, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0846, "heldPercentInsiders": 0.00254, "heldPercentInstitutions": 0.27724, "shortRatio": 0.95, "shortPercentOfFloat": 0.105, "bookValue": 0.929, "priceToBook": 2.0990312, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -29759000, "trailingEps": -1.72, "forwardEps": -1.54, "lastSplitFactor": "1:15", "lastSplitDate": 1624838400, "enterpriseToEbitda": -1.074, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TPST", "underlyingSymbol": "TPST", "shortName": "Tempest Therapeutics, Inc.", "longName": "Tempest Therapeutics, Inc.", "firstTradeDateEpochUtc": 1624887000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d54d822e-cd83-39cb-b46d-5c9b6edb9502", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.95, "targetHighPrice": 47.0, "targetLowPrice": 8.0, "targetMeanPrice": 18.6, "targetMedianPrice": 13.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 32326000, "totalCashPerShare": 1.455, "ebitda": -29206000, "totalDebt": 20371000, "quickRatio": 3.024, "currentRatio": 3.133, "debtToEquity": 98.735, "returnOnAssets": -0.45207, "returnOnEquity": -1.88366, "freeCashflow": -16672375, "operatingCashflow": -26240000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-19"}]